INS and diabetes mellitus: Together, these studies demonstrate that AAV-based therapies can achieve durable, regulated insulin expression through multiple tissue targets and regulatory mechanisms, while also highlighting critical challenges in prohormone processing and long-term safety that must be addressed as these approaches move toward clinical application for monogenic forms of diabetes like MODY10.